Navigation Links
AVANIR Pharmaceuticals Announces Fiscal 2011 First Quarter Financial Results
Date:2/3/2011

ALISO VIEJO, Calif., Feb. 3, 2011 /PRNewswire/ -- AVANIR Pharmaceuticals, Inc. (Nasdaq: AVNR) today reported unaudited financial results for the three months ended December 31, 2010.

For the first quarter of fiscal 2011, AVANIR reported a net loss of $12.1 million, or $0.11 loss per share, compared with a net loss of $4.8 million, or $0.06 loss per share, for the same period in fiscal 2010. Net revenues consisting primarily of royalty revenue were $1.8 million and $1.5 million for the first quarter of fiscal 2011 and fiscal 2010, respectively. Total operating expenses were $13.9 million in the first quarter of fiscal 2011, compared with $6.3 million in the comparable fiscal 2010 period. The increase in total operating expenses was primarily attributed to costs incurred in preparation for the commercial launch of NUEDEXTA™ (dextromethorphan hydrobromide and quinidine sulfate).  Cash used in operations during the first quarter of fiscal 2011 was $14.1 million.

"During the past quarter we continued to focus our efforts on preparing for a successful launch of NUEDEXTA, the first and only treatment for pseudobulbar affect," said Keith Katkin, AVANIR's President and CEO.  "With NUEDEXTA now available through retail pharmacies across the country and our experienced and dedicated sales force commencing physician promotion on February 7, 2011, we are thrilled to finally have NUEDEXTA available by prescription for the many patients in the U.S. suffering from PBA.  We are confident that we have the right strategy, resources and the sales and marketing expertise to ensure that NUEDEXTA is a long term commercial success."

RECENT HIGHLIGHTS AND UPCOMING MILESTONES:

CLINICAL PROGRAMS AND PIPELINE

  • Received FDA approval on October 29, 2010 for NUEDEXTA as the first and only
    '/>"/>

SOURCE AVANIR Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. AVANIR Pharmaceuticals Invites Investors to Fiscal 2010 Third Quarter Conference Call
2. AVANIR Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. AVANIR Pharmaceuticals Announces FDA Approval of NUEDEXTA™
4. AVANIR Pharmaceuticals Invites Investors to Conference Call Regarding FDA Approval of NUEDEXTA™ on Monday November 1, 2010
5. AVANIR Pharmaceuticals Announces Pricing of Public Offering of Common Stock
6. AVANIR Pharmaceuticals Announces NASDAQ Opening Bell Ceremony
7. AVANIR Pharmaceuticals Invites Investors to Fiscal 2011 First Quarter Conference Call
8. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
11. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... 23, 2013  Omeros Corporation (NASDAQ: ... Drug Application (IND) to evaluate OMS824 in Huntington,s ... and Drug Administration (FDA). OMS824 selectively inhibits phosphodiesterase ... the brain linked to a wide range of ... schizophrenia. OMS824 has shown promising results in animal ...
(Date:5/23/2013)... 2013 SynCardia Systems, Inc. ( www.syncardia.com ), ... Canada and CE ( Europe ) approved ... Centre in Scotland , which boasts ... SynCardia temporary Total Artificial Heart powered by the ... Bodyworks Exhibition, one of the most advanced exhibitions of ...
(Date:5/23/2013)... May 23, 2013  PAREXEL International Corporation (NASDAQ: ... presenting at the Jefferies Healthcare Conference in New York.  ... and Chief Financial Officer, will be making a presentation ... on Monday, June 3, 2013. A live ... "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
Breaking Medicine Technology:Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 2Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 3Investigational New Drug Application Cleared by FDA for OMS824 in Huntington's Disease 4Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3PAREXEL International To Present At Jefferies Healthcare Conference 2
... The U.S. Food and Drug Administration today approved ... to blood transfusions in patients with thalassemia, a genetic ... response to prior chelation therapy. (Logo: ... have excess iron in the body from the frequent ...
... Reata Pharmaceuticals, Inc. announced Friday a significant expansion ... program, bardoxolone methyl, and to continue advancing its earlier-stage ... executives: Paul Audhya, MD, as Vice ... Hilary Malone, Ph.D., as Vice President and Chief Regulatory ...
Cached Medicine Technology:FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 2FDA Approves Ferriprox to Treat Patients with Excess Iron in the Body 3Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 2Reata Pharmaceuticals Adds Executives to Management Team and Board of Directors 3
(Date:5/23/2013)... 2013 Cheap Concert Tickets announces that ... 2013 at stadiums throughout North America. This well known ... McCartney concert tickets to help McCartney fans see Sir Paul ... Tickets, states that she is also offering the customer appreciation ... Being a baby boomer, she is also a huge McCartney ...
(Date:5/23/2013)... THURSDAY, May 23 (HealthDay News) -- The sensation of ... be traced back to a small molecule released in ... mice. Researchers say this molecule, known as ... through the central nervous system. Ultimately, this signal is ... humans and mice are similar, the researchers concluded that ...
(Date:5/23/2013)... HealthDay Reporter , , THURSDAY, May 23 (HealthDay News) -- ... badly as methamphetamine or crack cocaine, a new study ... mouth, or ,coke mouth, it is startling to see ... the same," said Dr. Mohamed Bassiouny, a professor of ... in Philadelphia. Methamphetamine, crack cocaine and soda -- ...
(Date:5/23/2013)... Chinese and U.S. scientists have used virus isolated from ... to determine whether the virus could infect and be ... mammalian model in influenza research, and efficient transmission of ... how well the same process might occur in people. ... Institute of Allergy and Infectious Diseases, part of the ...
(Date:5/23/2013)... 23, 2013 Special Learning, Inc., ... educational resources for the autism, Down syndrome and ... opening its first global autism treatment center and ... August. This new world-class program is the first ... evidence-based practices to treat and deliver exceptional education ...
Breaking Medicine News(10 mins):Health News:Paul McCartney Tickets: Prices Slashed on Paul McCartney Tickets in Austin, Brooklyn, Tulsa, Memphis Washington DC, Milwaukee, Boston, Indianapolis, Regina and Seattle 2Health News:Got an Itch? Mouse Study May Help Explain Why 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 2Health News:Diet Soda Habit as Bad for Teeth as Meth Addiction, Study Claims 3Health News:Ferrets, pigs susceptible to H7N9 avian influenza virus 2Health News:Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines 2Health News:Special Learning, Inc. to Expand its Services for Individuals with Special Needs with Opening of New Special Education School in the Philippines 3
... SOUTH EASTON, Mass., March 10 Pressure,BioSciences, Inc. ... has moved its,corporate offices to 14 Norfolk Avenue ... accommodate the Company,s transition from an,early-stage, research and ... Schumacher, PBI,s Founder, President, and CEO,commented: "We now ...
... CT System Brings More Innovative Diagnostics to the ... ... March 10 Encouraged by the outstanding,marketing success of the worldwide ... ) announces the 510(k) market clearance of four,new applications aimed at ...
... bone damage and stunted growth , , MONDAY, March 10 ... may place pediatric patients at risk for bone damage ... new red flag concerns a signal transduction inhibitor (STI) ... medulloblastoma brain tumors by short-circuiting tumor growth on the ...
... University of Michigan Health System have found a key ... discovery that lends new insight into fibromyalgia, an often-baffling ... found, pain decreased when levels of the brain molecule ... which appears in the journal Arthritis and Rheumatism, could ...
... Donation Helps Provide Free Surgical Treatments for Children ... Operation Smile, a,worldwide children,s medical charity, today announced ... part of a ,sharing smiles, campaign,from Windows Live. ... physical,examinations and surgical treatment to children in 26 ...
... A study by the Woolcock Institute of Medical Research in ... very mild or well-controlled asthma, regular treatment with low dose ... , The study published in this months edition of Primary ... and compared the effects of inhaled corticosteroids (ICS) and placebo ...
Cached Medicine News:Health News:Pressure BioSciences, Inc. Announces Move to New Corporate Offices 2Health News:Siemens Introduces New Dual Energy Applications to SOMATOM Definition 2Health News:Siemens Introduces New Dual Energy Applications to SOMATOM Definition 3Health News:Siemens Introduces New Dual Energy Applications to SOMATOM Definition 4Health News:New Drug for Brain Cancer Too Dangerous for Pediatric Patients 2Health News:New Drug for Brain Cancer Too Dangerous for Pediatric Patients 3Health News:Pain in fibromyalgia is linked to changes in brain molecule 2Health News:Windows Live $500,000 Donation Commemorates Operation Smile's 25th Anniversary 2Health News:Treatment for mild asthma leads to improved lung function 2
... The Hub Cap Limited ... to provide outstanding fixation and ... targeted solution for four corner ... the plate offers the kind ...
... cornerstones of the Acutrak family are the ... Together they are used primarily for secure ... upper extremity, but have been used for ... stabilized with these two systems have ranged ...
... decade KMI® revolutionized the wrist arthroplasty market ... Wrist System. We're at it again, with ... the Universal2. Like the original, the Universal2 ... live with debilitating arthritis. To date, we ...
A straight suture punch with 2.5 mm needle and 2/0 to #1 monofilament suture....
Medicine Products: